Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293371 · ClinicalTrials.gov registry record · Phase 1
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00293371: Clinical Trial Phase 1 study, sponsored by University of California, San Francisco.
NCT00293371 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00293371, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving vatalanib together with docetaxel and prednisone may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of vatalanib when given together with docetaxel and prednisone and to see how well they work in treating patients with advanced prostate cancer.
Interventions
- DRUG prednisone
- DRUG docetaxel
- DRUG vatalanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-09 |
| Phase | Phase 1 |
Why NCT00293371 stopped before completion
NCT00293371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT00293371 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00293371 about?
NCT00293371 is a clinical study titled "Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer". RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by...
What is the current status of trial NCT00293371?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2005-02. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00293371?
The interventions under investigation include: prednisone (DRUG), docetaxel (DRUG), vatalanib (DRUG).
Who is sponsoring clinical trial NCT00293371?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00293371's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia